Observational studyFrontiers in immunology2026
A real-world multicenter study on postoperative adjuvant treatment patterns and prognostic implications following neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the widespread application of neoadjuvant immunochemotherapy (nICT) in locally advanced resectable esophageal squamous cell carcinoma (ESCC), determining the optimal postoperative adjuvant treatment strategy has become a critical clinical issue. This study aimed to evaluate the efficacy of different adjuvant treatment patterns and identify beneficial populations. Methods: This was a multicenter real-world study involving 612 ESCC patients from six national centers who underwent R0 resection after nICT. Patients were divided into three groups based on postoperative treatment patterns: Clinical Observation (CO group, n=337), Postoperative Adjuvant Chemotherapy (POCT group, n=80), and Postoperative Adjuvant Chemoimmunotherapy (POICT group, n=195). Study endpoints included overall survival (OS), disease-free survival (DFS), and recurrence patterns. Results: Multivariate analysis of the whole cohort showed that both POCT and POICT reduced the risk of death (HR = 0.51, P = 0.007; HR = 0.49, P<0.001) and disease progression (HR = 0.48, P = 0.003; HR = 0.48, P<0.001) compared with CO. Subgroup analysis indicated that among patients without pathological complete response (non-pCR), both POCT and POICT significantly improved OS and DFS (P<0.05), with no statistical difference between the two groups. In pCR patients, only POICT showed an OS benefit (P = 0.014). Patients with postoperative pathological stage III benefited in both OS and DFS (P<0.05) from POCT and POICT. After propensity score matching (PSM), the 3-year OS (74.7% vs 79.8%) and DFS (63.1% vs 67.2%) rates between the POCT and POICT groups showed no significant difference (P>0.05). Postoperative adjuvant therapy was an independent factor affecting OS in patients with more advanced yT, yN, and yTNM stages, and an independent prognostic factor for DFS in patients with yN2 stage and advanced yTNM stages. Failure pattern analysis revealed no statistically significant differences in the cumulative incidence of locoregional recurrence or distant metastasis between the POCT and POICT groups (χ²=0.279, 2.828; P = 0.597, 0.093). Conclusion: For ESCC patients receiving nICT, postoperative adjuvant treatment can provide survival benefits, particularly more pronounced in non-pCR patients and those with advanced postoperative pathological stages. Adding immunotherapy to chemotherapy did not significantly further improve survival outcomes in the overall PSM-matched population; however, in pCR patients, POICT showed OS benefit while POCT did not, suggesting potential differential efficacy according to pathological response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.